

Press Release

Eurofins Medinet Launches Virology Diagnostics Services with the Appointment of Yuory V. Karetnyi, M.D., Ph.D, as Program Director, Virology at Eurofins Medinet Washington DC

September 21, 2009 - Washington, DC

Eurofins Medinet is pleased to announce the appointment of Yuory V. Karetnyi, M.D., Ph.D. as Program Director, Virology, on September 21, 2009. Dr. Karetnyi will be responsible for developing, maintaining and performing laboratory assays for the detection and molecular characterization of microorganisms (including bacterial and viral pathogens) in clinical specimens with a heavier focus on viral diagnostics. Dr. Karetnyi will work closely with Eurofins Medinet's Chief Scientific Officer for Global Infectious Disease Services, Daniel F. Sahm, Ph.D., to advance Eurofins Medinet's leadership in laboratory and consultative services that support the biopharmaceutical industry's development of products for preventing, diagnosing, controlling, and treating infectious diseases caused by viruses. Dr. Karetnyi will report directly to Dr. Douglas Toal, Operations Director, Microbiology.

Dr. Karetnyi is a renowned virologist, with nearly 30 years experience in extensive cell culture, R&D, product development and testing experience in biotechnology and biopharmaceuticals gained in both industry and academia.

"We are very excited to welcome Dr. Karetnyi. His extensive experience establishing, validating, qualifying and supervising GLP- and cGMP-regulated testing programs, will enable us to rapidly expand our virology practice and better serve our clients needs to support their clinical trial drug development," said Gary Wnorowski, President of Eurofins Medinet Washington DC.

Prior to joining Eurofins Medinet, Yuory was Director of Microbiology and In Life Virology at WuXi AppTec Laboratory Services in St. Paul Minnesota where he established a cGMP cell culture/virology laboratory. Dr. Karetnyi also held positions as a Senior Development Scientist at Beckman Coulter; Research Scientist at the Cancer Center at the University of Iowa College of Medicine; NIH Training Grant Fellow and Houts-Arthritis Foundation Fellow at the Parvovirus Laboratory, Division of Rheumatology, Department of Internal Medicine at the University of Iowa College of Medicine.

Dr. Karetnyi earned a Ph.D. in Virology, from the L.A. Tarasevitch State Research Institute of Standardization & Control of Medical Biological Preparations, Ministry of Health of Russia, Moscow, as well as an M.D. from the I.M. Sechenov Moscow Medical Academy.

For more information about Eurofins Medinet, please visit us online at www.eurofinsmedinet.com or contact:

Eurofins Medinet Washington DC
Tel: +1 703 480-2500
Fax: +1 703 480-2654
Email: info@eurofinsmedinet.com

Notes for the editor:

About Eurofins Medinet

Eurofins Medinet provides a full range of global central laboratory testing services including safety parameters, biomarker development and analysis, and specialized testing in bioanalysis, pharmacokinetics, microbiology and genomics using its fully standardized and accredited central laboratories in Breda, the Netherlands, Washington DC and Denver USA, Paris, France, Singapore and Shanghai, China.

Eurofins – a global leader in bio-analysis

Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors.

With about 8,000 staff in more than 150 laboratories across 30 countries, Eurofins offers a portfolio of over 25,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to provide its customers with high quality services, accurate results in time and, if requested, expert advice by its highly qualified staff.

The Eurofins Group is one of the global market leaders in this field of applied life sciences. It intends to pursue its dynamic growth strategy and expand both its technology portfolio and its geographic reach. Through R&D, in-licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the NYSE Euronext Paris (ISIN FR0000038259) and Frankfurt (WKN 910251) Stock Exchanges (Reuters EUFI.LN, Bloomberg ERF FP, ESF, EUFI.DE).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.